Comparative Pharmacology
Head-to-head clinical analysis: HYDROXYZINE HYDROCHLORIDE versus PROMETHAZINE HYDROCHLORIDE PHENYLEPHRINE HYDROCHLORIDE W CODEINE PHOSPHATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROXYZINE HYDROCHLORIDE versus PROMETHAZINE HYDROCHLORIDE PHENYLEPHRINE HYDROCHLORIDE W CODEINE PHOSPHATE.
HYDROXYZINE HYDROCHLORIDE vs PROMETHAZINE HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydroxyzine hydrochloride is a first-generation antihistamine that acts as a competitive antagonist at histamine H1 receptors. It also possesses anticholinergic, antiemetic, and sedative properties. Its mechanism involves binding to H1 receptors in the gastrointestinal tract, uterus, blood vessels, and bronchial muscles, thereby inhibiting histamine-mediated effects.
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist, sedative, and antiemetic via central dopamine D2 and muscarinic M1 receptor blockade. Phenylephrine is a sympathomimetic amine that acts as a selective α1-adrenergic receptor agonist, causing vasoconstriction. Codeine is an opioid agonist at mu-opioid receptors, producing analgesia and antitussive effects, partly after O-demethylation to morphine.
25-100 mg orally or intramuscularly 3-4 times daily; maximum 600 mg/day.
Each 5 mL of oral solution contains promethazine hydrochloride 6.25 mg, phenylephrine hydrochloride 5 mg, and codeine phosphate 10 mg. Adult dose: 5 mL every 4 to 6 hours as needed. Maximum 30 mL per day.
None Documented
None Documented
Terminal elimination half-life is approximately 20-25 hours in adults. In elderly or hepatic impairment, may be prolonged. Clinical context: Achieves steady-state after ~4-5 days; detectable for >72 hours after cessation.
Promethazine: 9-16 h (adults); prolonged in hepatic impairment. Phenylephrine: 2-3 h (oral); 5-10 min (IV due to rapid redistribution). Codeine: 2.5-3.5 h; active metabolites (morphine) 2-3 h.
Primarily hepatic metabolism via CYP3A4 and CYP3A5; <1% excreted unchanged in urine. Renal elimination of metabolites (approx. 50-60% of total clearance), with minor fecal excretion (<10%).
Promethazine: ~70% renal as metabolites, minor biliary/fecal. Phenylephrine: ~86-96% renal as metabolites (sulfate and glucuronide conjugates). Codeine: ~90% renal, primarily as morphine and norcodeine conjugates; 5-10% unchanged. Fecal excretion minimal.
Category A/B
Category A/B
Antihistamine
Antihistamine / Antiemetic